– USA, CA – Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company, announced the appointment of Dr. Alison Moore (Ph.D.) to its Board as an Independent Director, bringing over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing.
“We are honored to welcome Alison to the Artiva Board of Directors. Her decades of executive experience in manufacturing and technical operations across modalities, specifically in allogenic cell therapies, will bring an important perspective to our team as we advance our pipeline in the clinic,” said CEO Dr. Fred Aslan. “In parallel to our efforts to evaluate the efficacy and safety of AlloNK, we believe the extensive history of our manufacturing process sets us apart from our allogeneic cell therapy peers, potentially accelerating our path to bring this experimental therapy to patients.”
About Dr. Alison Moore
Dr. Alison Moore serves as CTO of Codexis Inc. (Nasdaq: CDXS), a leading enzyme engineering company, and was the former CTO of Allogene Therapeutics (Nasdaq: ALLO), a pioneering clinical-stage company advancing CAR T-cell therapies.
Dr. Alison Moore said, “I have been impressed with the scalability and robustness of AlloNK’s manufacturing process at this stage of development. Built on a decade of leadership, the lack of genetic engineering simplifies the manufacturing process, and the clinical experience to date suggests this therapy offers a compelling approach to depleting B cells and potentially addressing the unmet need for patients with devastating autoimmune diseases and cancers. I am excited to join the board at this critical point in Artiva’s evolution to help realize the full potential of AlloNK for the treatment of autoimmune disease and cancer.”
Before Codexis and Allogene, Dr. Alison Moore spent 20 years at Amgen, most recently as SVP of Process Development, with leadership roles in Supply Chain and Manufacturing. Before joining Amgen, she held positions at Genentech in chemistry, manufacturing, and regulatory affairs.
Dr. Alison Moore holds a bachelor’s degree in pharmacology with Honors and a Ph.D. in Cell Biology from Manchester University, England.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently in clinical trials for the treatment of systemic lupus erythematosus, for patients with or without lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin-out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, under a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia, and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
For more: https://www.artivabio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.